Statutory Price Disclosure for Vermont Prescribers: Long Forms
- BOSULIF® (bosutinib) tablets, for oral use (PDF)
- BRAFTOVI® (encorafenib) capsules (PDF)
- CIBINQO™ (abrocitinib) tablet, for oral use (PDF)
- DAURISMO™ (glasdegib) tablets, for oral use (PDF)
- DUAVEE® (conjugated estrogens/bazedoxifene) tablets (PDF)
- ELIQUIS® (apixaban) tablets for oral use (PDF)
- IBRANCE® (palbociclib) capsules, for oral use (PDF)
- INLYTA® (axitinib) tablets for oral administration (PDF)
- LITFULO™ (ritlecitinib) capsules, for oral use (PDF)
- LORBRENA® (lorlatinib) tablets, for oral use (PDF)
- MEKTOVI® (binimetinib) tablets (PDF)
- NURTEC®ODT (rimegepant) orally disintegrating tablets (ODT), for sublingual or oral use (PDF)
- OXBRYTA® (voxelotor) tablets (for oral use, for oral suspension) (PDF)
- PREMARIN® (conjugated estrogens tablets, USP) (PDF)
- SUTENT® (sunitinib malate) capsules (PDF)
- TALZENNA™ (talazoparib) capsules (PDF)
- TOVIAZ™ (fesoterodine fumarate) extended-release capsules (PDF)
- VIZIMPRO® (dacomitinib) tablets (PDF)
- XALKORI® (crizotinib) capsules, oral (PDF)
- XELJANZ® (tofacitinib) tablets for oral administration (PDF)
- XTANDI® (enzalutamide) capsules, for oral use (PDF)
- ZYVOX™ (linezolid) tablets (PDF)